PURE Bioscience (OTCMKTS:PURE) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday.
Shares of PURE Bioscience (OTCMKTS:PURE) traded down 0.99% during midday trading on Tuesday, hitting $1.00. The stock had a trading volume of 18,500 shares. The firm’s market cap is $62.71 million. PURE Bioscience has a 12 month low of $0.75 and a 12 month high of $1.36. The stock’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.07.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/2887450/pure-bioscience-pure-stock-rating-lowered-by-valuengine.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.